With a push to lower the commercial price tags of new drugs – and find ways to get them to market sooner – pharmaceutical companies and regulatory bodies are increasingly more open to new clinical trial methodologies and tools. In parallel, during the current COVID-19 pandemic, the pharmaceutical industry is further forced to shift away from traditional clinical trial modalities with a bricks-and-mortar approach to a more patient-centric approach, where the trial comes to the patients in the form of digital enablement. Now is the time for innovation in clinical trials.